AffyImmune Therapeutics
Dr. James Mulé is the Associate Center Director for Translational Science, Interim Associate Center Director for Basic Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Scientific Director of Cell Based Therapies at the Moffitt Cancer Center. Dr. Mulé, who was designated a “Master of Immunology” by the American Association for Cancer Research’s journal Cancer Immunology Research, is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in solid tumors. His clinical research group is involved in developing and validating genomic signatures of immunotherapy response to recognize and destroy tumors. The translational work in these areas has helped to develop new treatments for advanced cancer patients.
This person is not in the org chart
This person is not in any offices
AffyImmune Therapeutics
AffyImmune Therapeutics is a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers.